Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5214155 | 0.88 | AVPR1A (0.49) | AVPR1A | |
| SCHEMBL5214011 | 0.82 | AVPR1A (0.69) | AVPR1A | |
| SCHEMBL5215865 | 0.81 | AVPR1A (0.59) | AVPR1A | |
| SCHEMBL5010810 | 0.79 | AVPR1A (1.00) | AVPR1A | |
| SCHEMBL5215652 | 0.79 | AVPR1A (0.55) | AVPR1A | |
| SCHEMBL5215914 | 0.78 | AVPR1A (1.00) | AVPR1A | |
| SCHEMBL5010805 | 0.74 | AVPR1A (1.00) | AVPR1A | |
| SCHEMBL5008987 | 0.74 | AVPR1A (1.00) | AVPR1A | |
| SCHEMBL5216020 | 0.74 | AVPR1A (0.83) | AVPR1A | |
| SCHEMBL5215084 | 0.74 | AVPR1A (0.48) | AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558598-B1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LTD (GB) | 2007-07-18 | — | — | EP | claimed |
| US-7084145-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2006-08-01 | — | — | US | claimed |
| EP-1558598-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | Pfizer Limited (GB) | 2005-08-03 | — | — | EP | claimed |
| US-20040162278-A1 | Triazole compounds useful in therapy | PFIZER INC | 2004-08-19 | — | — | US | claimed |
| WO-2004037809-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LIMITED (GB) | 2004-05-06 | — | — | WO | claimed |
| EP-1656183-B1 | TREATMENT OF MALE SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2007-12-05 | — | — | EP | disclosed |
| EP-1558598-B1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LTD (GB) | 2007-07-18 | — | — | EP | disclosed |
| US-7084145-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1656183-A1 | TREATMENT OF MALE SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2006-05-17 | — | — | EP | disclosed |
| EP-1558598-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | Pfizer Limited (GB) | 2005-08-03 | — | — | EP | disclosed |
| US-20050026810-A1 | Treatment of male sexual dysfunction | PFIZER INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2005006899-A1 | TREATMENT OF MALE SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2005-01-27 | — | — | WO | disclosed |
| US-20040162278-A1 | Triazole compounds useful in therapy | PFIZER INC | 2004-08-19 | — | — | US | disclosed |
| WO-2004037809-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162278-A1 | Triazole compounds useful in therapy | AVPR2, AVPR1B, AVPR1A | AVPR1A 3/4885 |
| US-20050026810-A1 | Treatment of male sexual dysfunction | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.